Equities Analysts Offer Predictions for ABOS FY2025 Earnings

Acumen Pharmaceuticals, Inc. (NASDAQ:ABOS) – Stock analysts at Cantor Fitzgerald issued their FY2025 earnings per share estimates for shares of Acumen Pharmaceuticals in a report issued on Tuesday, January 21st. Cantor Fitzgerald analyst P. Stavropoulos anticipates that the company will post earnings per share of ($1.97) for the year. The consensus estimate for Acumen Pharmaceuticals’ current full-year earnings is ($1.56) per share.

Acumen Pharmaceuticals (NASDAQ:ABOS) last released its earnings results on Tuesday, November 12th. The company reported ($0.50) earnings per share for the quarter, missing the consensus estimate of ($0.36) by ($0.14). During the same period last year, the company posted ($0.24) earnings per share.

Separately, HC Wainwright reiterated a “buy” rating and issued a $15.00 price target on shares of Acumen Pharmaceuticals in a report on Wednesday, November 13th.

Acumen Pharmaceuticals Trading Up 6.1 %

Shares of ABOS opened at $1.73 on Thursday. The company has a debt-to-equity ratio of 0.14, a current ratio of 10.43 and a quick ratio of 10.43. The firm has a market capitalization of $103.94 million, a price-to-earnings ratio of -1.25 and a beta of 0.02. The company has a 50-day moving average of $1.98 and a 200 day moving average of $2.46. Acumen Pharmaceuticals has a 1-year low of $1.53 and a 1-year high of $5.09.

Hedge Funds Weigh In On Acumen Pharmaceuticals

A number of large investors have recently made changes to their positions in ABOS. Franklin Resources Inc. increased its holdings in shares of Acumen Pharmaceuticals by 5.4% during the 3rd quarter. Franklin Resources Inc. now owns 3,549,069 shares of the company’s stock valued at $8,340,000 after purchasing an additional 181,451 shares in the last quarter. FMR LLC raised its stake in shares of Acumen Pharmaceuticals by 0.3% during the 3rd quarter. FMR LLC now owns 2,028,117 shares of the company’s stock worth $5,030,000 after buying an additional 6,014 shares during the period. Geode Capital Management LLC lifted its position in shares of Acumen Pharmaceuticals by 6.5% during the 3rd quarter. Geode Capital Management LLC now owns 864,528 shares of the company’s stock valued at $2,144,000 after buying an additional 52,395 shares in the last quarter. State Street Corp increased its holdings in Acumen Pharmaceuticals by 18.3% in the 3rd quarter. State Street Corp now owns 516,406 shares of the company’s stock worth $1,281,000 after acquiring an additional 79,841 shares in the last quarter. Finally, Renaissance Technologies LLC acquired a new stake in shares of Acumen Pharmaceuticals in the second quarter valued at about $818,000. 71.01% of the stock is owned by institutional investors and hedge funds.

Insiders Place Their Bets

In other Acumen Pharmaceuticals news, CEO Daniel Joseph Oconnell sold 47,778 shares of the company’s stock in a transaction on Friday, January 3rd. The stock was sold at an average price of $1.84, for a total transaction of $87,911.52. Following the completion of the sale, the chief executive officer now owns 454,707 shares in the company, valued at $836,660.88. This represents a 9.51 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Insiders have sold a total of 79,508 shares of company stock worth $146,556 in the last three months. Corporate insiders own 7.10% of the company’s stock.

Acumen Pharmaceuticals Company Profile

Acumen Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops targeted therapies for the treatment of Alzheimer’s disease. The company focuses on advancing a targeted immunotherapy drug candidate sabirnetug (ACU193), a recombinant humanized immunoglobulin gamma 2 that completed Phase I clinical trial to target soluble amyloid-beta oligomers.